Journal of Pharmacological Biomolecules and Therapeutics

ETERNO PRESS

Review

The Kinase Chemirevolution: How the Discovery of Protein Kinases and 25 Years of Molecular Innovation Reshaped Modern Medicine

Saminesh Kumar, Stalin Arulsamy, Rajesh Kumar, Shivank Sharma*

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

*Corresponding Author: Shivank Sharma, shivanksharma024@gmail.com

Abstract

The discovery of protein kinases and the subsequent development of small-molecule inhibitors represent one of the most transformative achievements in modern pharmacology. This review chronicles the history of the Kinase Chemirevolution, tracing these enzymes from their early identification as regulators of glycogen metabolism to their current status as the second-most targeted protein family in the human genome, surpassed only by G-protein-coupled receptors (GPCRs). We examine the key biological discoveries that established kinases as central architects of cellular communication, including the identification of the Src oncogene and the breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein, which first linked phosphorylation to malignancy. The chemical evolution of kinase-targeting strategies is discussed in depth: from the first-generation adenosine triphosphate (ATP)-competitive inhibitors exemplified by imatinib, to second-generation scaffolds developed to overcome resistance mutations, and finally to third-generation covalent inhibitors that irreversibly silence their targets. We also examine the fourth wave of modalities, including allosteric modulators that exploit non-conserved regulatory pockets for superior selectivity, and Proteolysis-Targeting Chimeras (PROTACs) that catalytically eliminate disease-relevant kinases via the ubiquitin-proteasome system. The convergence of structural biology, medicinal chemistry, and clinical oncology has produced a field of profound scientific and clinical impact. The Lasker Award (2009) conferred upon Brian Druker, Nicholas Lydon, and Charles Sawyers reflects the magnitude of this achievement. This review incorporates data on over 70 Food and Drug Administration-approved kinase inhibitors as of 2025, including recent agents such as the HER2-selective zongertinib and the artificial intelligence (AI)-designed rentosertib. We argue that the next frontier–defined by the convergence of generative AI, systems-level network pharmacology, and autonomous discovery laboratories–will further revolutionize precision medicine.

Keywords

Protein kinases, Small-molecule inhibitors, Oncogenic phosphorylation, Allosteric modulation, PROTACs, AI-driven precision drug discovery

Article History

Received: 15 December 2025 Revised: 18 March 2026

Accepted: 01 April 2026 Available Online: 09 April 2026

1. Introduction

1.1 Historical Background of Kinases

The concept of reversible protein phosphorylation–now recognized as the primary language of intracellular signal transduction–was not immediately accepted as a fundamental regulatory process. Early 20th-century enzymology focused predominantly on metabolic pathways, with phosphorylase kinase recognized as one of the principal enzymes governing glycogen breakdown. The pioneering work of Edmond Fischer and Edwin Krebs in the 1950s elucidated the mechanism of phosphorylation and dephosphorylation, for which they were awarded the Nobel Prize in Physiology or Medicine in 1992. For decades thereafter, however, kinases remained categorized as metabolic regulators rather than broader signaling enzymes [1-6].

A transformative shift occurred in the late 1970s and early 1980s, when the transforming gene of the Rous sarcoma virus (v-Src) was found to encode a protein kinase capable of phosphorylating tyrosine residues [7,8]. This discovery directly implicated kinase activity in oncogenesis, fundamentally changing the perception of these enzymes from metabolic housekeepers to decisive mediators of cancer. Subsequent mapping of the human kinome–comprising 518 protein kinases–revealed a vast and interconnected superfamily involved in cell division, differentiation, apoptosis, and motility [9,10]. These pivotal findings established kinases as central architects of oncogenic signaling and validated phosphorylation as a key molecular driver of malignancy.

1.2 Evolution from Signaling Enzymes to Drug Targets

The transition of kinases from objects of biological curiosity to validated pharmaceutical targets was driven by molecular oncology [11,12]. The identification of the Philadelphia chromosome–the cytogenetic hallmark of chronic myeloid leukemia (CML)–provided the crucial mechanistic link. This chromosomal translocation fuses the breakpoint cluster region (BCR) and abelson murine leukemia viral oncogene homolog 1 (ABL) genes, producing a chimeric protein with constitutively active tyrosine kinase activity, which directly drives leukemic transformation. This discovery provided the rational justification for pharmacologically targeting a single kinase to treat an entire disease [13,14].

Unlike cytotoxic chemotherapy, which indiscriminately targets rapidly dividing cells, kinase inhibitors offer a molecularly specific intervention. Although the high conservation of the adenosine triphosphate (ATP)-binding pocket across the kinome initially raised concerns about achievable selectivity, subsequent structural studies demonstrated that subtle variations in the hinge region and activation loop could be exploited to design highly selective inhibitors [15,16].

1.3 Why Kinases Represent a Paradigm Shift in Medicine

The clinical success of kinase inhibitors marked the beginning of targeted, precision oncology, replacing the broad-spectrum cytotoxic approach that characterized mid-20th-century cancer therapy [17,18]. This paradigm shift moved treatment strategies from empirical classification by tissue of origin (e.g., "lung cancer") to mechanism-based molecular stratification (e.g., "EGFR-mutant non-small cell lung cancer [NSCLC]"). Because kinases function as binary molecular switches–driving the disease phenotype when locked in the "on" position due to mutation or overexpression—they represent ideal nodes for pharmacological intervention [19].

The concept of "oncogene addiction," whereby a tumor becomes dependent on a single hyperactive signaling pathway for survival, explains why kinase inhibitor-induced pathway collapse can produce substantial clinical responses with manageable toxicity profiles compared to conventional chemotherapy. This principle has since extended beyond oncology to autoimmune diseases, where JAK inhibitors modulate cytokine-driven inflammation, and to metabolic disorders, fundamentally reshaping 21st-century pharmacotherapy [20].

1.4 Overview of the "Kinase Chemirevolution"

The period spanning the late 1990s through 2025 is referred to herein as the "Kinase Chemirevolution"–an era defined not merely by the discovery of new drugs, but by the development of entirely novel chemical inhibition paradigms [21,22]. The revolution began with Type I and Type II ATP-competitive inhibitors, which exploit conformational differences between the active and inactive states of the kinase. It subsequently evolved to encompass covalent inhibition (warheads that form irreversible bonds with specific cysteine residues) and allosteric modulation (targeting pockets topographically remote from the active site) [23,24].

Most recently, the field has embraced targeted protein degradation via PROTACs, which harness the cell's UPS to completely eliminate the kinase rather than merely inhibit its activity [4,25]. In parallel with the reticular chemistry revolution in materials science–which gave rise to Metal-Organic Frameworks through modular design–kinase inhibitors have become a modular toolkit for controlling biological signaling, enabling precise manipulation of information flow within living cells. These modalities–from allosteric modulators to PROTACs–collectively define the modern kinase inhibitor toolkit.

1.5 Scope and Significance of this Review

This review aims to provide a comprehensive, historically grounded, and clinically current account of the Kinase Chemirevolution from a 2025 perspective. It integrates historical analysis with contemporary discoveries, including Phase 3 data on vepdegestrant (an estrogen receptor [ER] PROTAC) and the approval of zongertinib (a HER2-selective inhibitor that spares EGFR). We examine the medicinal chemistry strategies employed to overcome resistance, the structural biology underpinning rational drug design, and the societal impact of these therapeutics. By integrating data from academic literature, clinical trials, and industry reports, we demonstrate how the convergence of chemistry, biology, and artificial intelligence is actively addressing the challenge of drug resistance

2. Literature Search Strategy and Methodology

2.1 Search Databases and Terms

A comprehensive literature search was conducted to map the full landscape of kinase drug discovery, encompassing foundational papers from 1990 through the latest clinical data available in 2025 [26,27]. Primary databases searched included PubMed/MEDLINE, Web of Science, Scopus, and the Protein Data Bank (PDB). Keywords employed included "Protein Kinase Inhibitor," "Covalent Inhibitor," "Allosteric Modulation," "PROTAC," "Targeted Protein Degradation," "Drug Resistance Mechanisms," and "Artificial Intelligence in Drug Discovery." Search terms were combined using Boolean operators: ("Kinase" OR "Phosphotransferase") AND ("Inhibitor" OR "Degrader") AND ("Clinical Trial" OR "FDA Approval") AND ("1990-2025"). For AI-focused sections, additional terms including "Generative Chemistry," "Deep Learning," and "Self-Driving Laboratory" were combined with "Kinase" [28].

Supplementary searches were conducted in ClinicalTrials.gov for active study status, the CoRE (Computation-Ready, Experimental) structural database, FDA approval databases, and patent filings. Industry press releases from Novartis, AstraZeneca, Arvinas, and Insilico Medicine were reviewed for pipeline information current as of late 2025 [29,30].

2.2 Inclusion and Exclusion Criteria

To ensure comprehensive historical coverage, the temporal scope of this review encompasses literature from 1990 to 2025. Studies were included if they: (i) provided mechanistic insights into kinase inhibition; (ii) reported novel chemical structures supported by structure-activity relationship data; or (iii) detailed results from Phase I to Phase III clinical trials with clearly defined efficacy endpoints, such as objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) [31,32]. Priority was given to structural studies employing X-ray crystallography or cryo-electron microscopy (cryo-EM) to clarify drug-target interactions.

Studies were excluded if they: (i) reported non-selective or clinically non-translatable inhibitor classes without comparative historical value; (ii) presented purely computational findings without experimental validation, except for landmark AI-driven contributions (e.g., the AlphaFold paradigm); or (iii) could not be verified as peer-reviewed primary sources. Theses, unpublished manuscripts, and informal book reviews were excluded in favor of peer-reviewed primary literature [33]. The complete literature search and selection process is detailed in Supplementary Figure 1.

2.3 Data Categorization and Thematic Grouping

Extracted data were organized into five thematic pillars: (i) structural biology, including DFG-in/DFG-out conformations, gatekeeper residues, and regulatory spine architecture [34,35]; (ii) medicinal chemistry, encompassing scaffold evolution, warhead chemistry, and linker design strategies for PROTAC development; (iii) clinical pharmacology, covering pharmacokinetic/pharmacodynamic (PK/PD) relationships, resistance mechanisms, and toxicity profiles; (iv) technological innovations, specifically the contributions of cryo-EM and AI/machine learning to discovery timelines; and (v) industrial metrics, including regulatory approvals, manufacturing challenges, and sustainability considerations [36,37].

2.4 Limitations of this Review

This review acknowledges the inherent limitation of a rapidly evolving field. Potency or selectivity values described as state-of-the-art in early 2025 may be superseded by subsequent publications. Additionally, cross-trial comparisons are constrained by differences in patient populations, prior therapies, and mutation status. Where possible, direct trial data–such as VERITAC-2 for PROTACs–are cited in preference to historical controls.

3. Kinase Biology and Inhibitor Chemistry

3.1 The Chemistry and Biology of Kinase Structure

The human kinome constitutes the primary signaling control network of the cell, with 518 kinase enzymes catalyzing the transfer of the γ-phosphate from ATP to hydroxyl-bearing residues including serine (Ser), threonine (Thr), and

tyrosine (Tyr) [38]. Despite their diverse biological roles, these enzymes share a highly conserved bilobal catalytic domain architecture, which has been central to both the challenges and successes of kinase drug discovery.

3.1.1 The Bilobal Fold

The N-terminal lobe (N-lobe) is predominantly composed of β-sheets, while the larger C-terminal lobe (C-lobe) consists primarily of α-helices. These two lobes are connected by a flexible hinge region. The ATP molecule binds within a deep cleft between the lobes, stabilized by hydrogen bonds to the hinge backbone. Although this conservation initially raised concerns about pan-kinase toxicity from ATP-site inhibitors, subsequent structural and biochemical studies demonstrated that subtle variations in the size, electrostatic character, and flexibility of this pocket provide sufficient differentiation for selective drug design [39,40].

3.1.2 The DFG Motif and Activation Loop

The core regulatory switch of the kinase is the activation loop (A-loop), which begins with the conserved Asp-Phe-Gly (DFG) motif. In the catalytically active DFG-in conformation, the aspartate residue coordinates magnesium ions essential for catalytic phosphoryl transfer, while the phenylalanine contributes to the hydrophobic regulatory spine (R-spine) that stabilizes the active kinase architecture [41,42]. In the inactive DFG-out conformation, this motif rotates approximately 180°, displacing the aspartate from the active site, occluding the ATP-binding pocket with the phenylalanine side chain, and simultaneously exposing an adjacent hydrophobic allosteric pocket. Type II kinase inhibitors, which specifically stabilize this DFG-out state, generally achieve superior selectivity because inactive kinase conformations exhibit substantially greater structural diversity than their active counterparts [43] (Figure 1). The major kinase inhibitor binding classes and representative examples are summarized in Table 1.



Figure 1. Schematic illustration of kinase activation loop switching. (A) DFG-in (active) conformation with the aspartate coordinating Mg^{2+} ions for phosphoryl transfer. (B) DFG-out (inactive) conformation with the phenylalanine occluding the ATP pocket and exposing the adjacent allosteric hydrophobic pocket exploited by Type II inhibitors.

Table 1. Classification of kinase inhibitor binding modes.

Class	Binding Site	Conformation Targeted	Example Drug	Key Characteristic
Type I	ATP Pocket	Active (DFG-in)	Gefitinib, Dasatinib	High potency; selectivity challenges due to conserved active site [44].
Type II	ATP + Allosteric	Inactive (DFG-out)	Imatinib, Sorafenib	Stabilizes inactive state; superior selectivity profile [45].
Type III	Allosteric (Proximal)	Variable	Trametinib	Binds adjacent to ATP site; non-competitive with ATP [46].
Type IV	Allosteric (Distal)	Variable	Asciminib	Binds remote from ATP site (myristoyl pocket); exquisite selectivity [47].
Covalent	ATP Pocket + Cys	Active or Inactive	Osimertinib, Ibrutinib	Forms irreversible bond with Cys residue; infinite residence time [48].
PROTAC	Surface Lysines	Any	Vepdegestrant (ARV-471)	Binds target and E3 ligase; induces ubiquitination and proteasomal degradation [49].

3.2 Landmark Discoveries in Kinase Biology

3.2.1 The BCR-ABL Oncogene and the Philadelphia Chromosome

The discovery of the Philadelphia chromosome in 1960 established the first direct link between a specific chromosomal abnormality and a human malignancy [50]. Decades of subsequent molecular work revealed that this translocation fuses the BCR and ABL genes, generating a constitutively active tyrosine kinase. This single molecular lesion is both necessary and sufficient for the development of CML, providing compelling mechanistic justification for a targeted therapeutic approach. The landmark EGFR mutation studies of Lynch and colleagues [51] and Paez and colleagues [52], both published in the New England Journal of Medicine and Science respectively in 2004, extended this principle to solid tumors, demonstrating that activating mutations in EGFR predict dramatic responses to gefitinib in NSCLC patients.

3.2.2 Imatinib: Proof of the Targeted Therapy Principle

The development of imatinib (Gleevec) by Novartis—driven critically by the work of Brian Druker, Nicholas Lydon, and Charles Sawyers—represented a watershed moment in oncology drug discovery. The landmark Phase II clinical trial published by Druker and colleagues in the New England Journal of Medicine in 2001 reported complete hematologic responses in 98% and complete cytogenetic responses in 54% of newly diagnosed CML patients in chronic phase [53]. Unlike earlier non-selective inhibitors, imatinib was rationally designed to bind the inactive (DFG-out) conformation of the ABL kinase, achieving high specificity by locking the enzyme in an inactive state. Its approval in 2001 validated the entire paradigm of targeted molecular therapy and demonstrated that diseases driven by single molecular defects could be durably controlled. The Lasker Award in 2009 formally recognized this achievement as a landmark of translational medicine.

The structural basis for imatinib's selectivity was subsequently elucidated by Schindler and colleagues in Science in 2000 [54], who demonstrated through co-crystal structural analysis that imatinib engages the inactive DFG-out conformation of ABL with extraordinary specificity—a finding that directly guided subsequent generations of kinase inhibitor design.

3.3 Chemical Strategies for Modern Kinase Inhibitors

3.3.1 Overcoming Gatekeeper Mutations: Second- and Third-Generation Inhibitors

The T315I gatekeeper mutation—arising from substitution of threonine 315 with isoleucine in the BCR-ABL kinase—became the paradigmatic example of on-target acquired resistance to first-generation inhibitors [55,56]. By sterically occluding the binding site of imatinib and related agents, this single amino acid substitution caused clinical relapse in a significant proportion of treated patients. Second-generation inhibitors, including dasatinib (Type I) and nilotinib (Type II), substantially improved potency against most resistance mutations but remained ineffective against T315I. This challenge was ultimately addressed by ponatinib, engineered with a rigid acetylene linker that geometrically bypasses the isoleucine side chain, restoring drug binding and clinical efficacy in T315I-positive CML [57,58].

3.3.2 Covalent Inhibition: The Irreversible Strategy

The T790M mutation in EGFR—analogous to T315I in ABL—confers resistance to first- and second-generation EGFR inhibitors by increasing affinity for ATP [59,60]. Osimertinib was designed with an acrylamide warhead that selectively reacts with Cysteine 797 at the rim of the EGFR active site, forming a permanent covalent bond that renders the drug's efficacy independent of competitive ATP concentrations. Preclinical and clinical data demonstrated that this covalent strategy overcame T790M-driven resistance, and osimertinib subsequently demonstrated superiority over earlier agents as first-line therapy in EGFR-mutant NSCLC, with a median PFS of 18.9 months. The drug's superior central nervous system penetration further cemented its role as the standard of care [61,62].

The original Sakamoto and colleagues PROTAC concept, published in the Proceedings of the National Academy of Sciences in 2001 [63], provided the theoretical framework for catalytic protein destruction that would later converge with covalent chemistry principles to produce the modern degrader landscape.

3.3.3 Allosteric Modulation: The Fourth Wave

As on-target resistance mutations proliferated and the intellectual property landscape of ATP-competitive inhibitors became crowded, medicinal chemists systematically pursued allosteric binding sites topographically removed from the ATP pocket [64,65]. Asciminib, the first-in-class specifically targeting the ABL myristoyl pocket (STAMP inhibitor), exemplifies this strategy. By binding to the myristoyl pocket—a site mechanistically and topographically distinct from the ATP pocket—asciminib mimics the natural autoinhibitory myristoyl group, maintaining BCR-ABL in its inactive conformation. This mechanism retains activity against ATP-site resistance mutations including T315I and enables a "double-clamp" inhibitory strategy when combined with ATP-competitive agents.

The 2025 approval of zongertinib further illustrated the clinical value of extreme kinase selectivity. Engineered to engage the HER2 kinase domain while sparing the closely homologous EGFR, zongertinib demonstrated an ORR of 35% in HER2-mutant NSCLC [66]. Its kinome selectivity panel confirms minimal off-target activity, translating to a substantially improved tolerability profile compared to pan-HER inhibitors, with reduced incidence of EGFR-mediated gastrointestinal and dermatological toxicities.

3.3.4 PROTACs: Catalytic Protein Degradation

The conceptual transition from kinase inhibition to kinase elimination represents a fundamental paradigm shift in targeted therapy. PROTACs are bifunctional molecules: one end binds the target kinase, while the other recruits an E3 ubiquitin ligase (typically cereblon or von Hippel-Lindau [VHL] protein), bringing the two into proximity and facilitating ubiquitination and subsequent proteasomal degradation of the target [67,68]. Critically, PROTACs operate catalytically–a single PROTAC molecule can cycle through multiple rounds of target ubiquitination and proteasomal destruction, enabling sustained pathway suppression at lower drug concentrations.

Vepdegestrant (ARV-471), an ER-targeting PROTAC, has advanced to Phase III clinical trials (VERITAC-2) for hormone receptor-positive (HR^+)/HER2-negative breast cancer. It demonstrates activity against ligand-binding domain mutations (e.g., ESR1 mutations) that confer resistance to endocrine therapies. BGB-16673, a BTK PROTAC, addresses resistance arising from the C481S mutation that abrogates covalent ibrutinib binding, demonstrating the unique ability of degraders to overcome mutations in the drug-binding cysteine residue [69].

3.4 Structural Biology and Target Engagement

Advances in structural biology have been essential drivers of the kinase chemirevolution. X-ray crystallography has provided atomic-resolution co-crystal structures–including imatinib bound to ABL [54] and osimertinib bound to T790M/C797S EGFR [70]–that revealed hydrogen-bonding networks, steric constraints, and binding determinants that directly informed next-generation inhibitor design. In the 2020s, cryo-EM has enabled visualization of large multiprotein kinase assemblies, including mTOR complex 1 (mTORC1) and phosphoinositide 3-kinase (PI3K), whose complexity had previously precluded crystallographic analysis. This capability has been critical for the development of allosteric inhibitors targeting interfacial sites invisible in isolated kinase domain structures.

Modern kinase drug discovery increasingly emphasizes kinetic profiling–specifically target residence time–rather than equilibrium binding affinity (Kd) alone. This reflects the clinical observation that covalent inhibitors achieve theoretically infinite residence time, while reversible inhibitors with slow dissociation rates (koff) show improved in vivo efficacy due to extended pharmacodynamic duration, even when the free drug concentration falls below the Kd [48,71].

3.5 Clinical Landscape of Kinase Inhibitors (2025)

3.5.1 Oncology

Kinase-targeted therapies have transformed the clinical management of multiple malignancies [66,72]. In NSCLC, the successive development of first-generation EGFR inhibitors (gefitinib, erlotinib), second-generation agents (afatinib), and third-generation osimertinib has converted EGFR-mutant lung cancer–historically one of the most rapidly lethal malignancies–into a condition manageable over several years. Recent 2025 approvals including sevabertinib and zongertinib further extend the therapeutic options for patients with acquired resistance or HER2-mutant disease. In CML, long-term therapy with imatinib or the allosteric agent asciminib has enabled life expectancies approaching those of age-matched controls. In chronic lymphocytic leukemia (CLL), Bruton's tyrosine kinase (BTK) inhibitors including ibrutinib and pirtobrutinib have largely supplanted conventional chemoimmunotherapy [73,74].

3.5.2 Autoimmune and Inflammatory Disease

JAK Inhibitors: Drugs such as tofacitinib and upadacitinib block the JAK signaling cascade, interrupting cytokine-mediated inflammation in rheumatoid arthritis and ulcerative colitis. BTK Inhibitors: Beyond oncology, BTK inhibition is being investigated for multiple sclerosis to manage B cell-driven neuroinflammation. Clinical performance metrics for representative kinase inhibitors across these indications are summarized in Table 2.

Table 2. Performance metrics of representative clinical kinase inhibitors (2025 landscape).

Drug Name	Target	Mechanism (Type)	Clinical Metric (Trial; Phase)	Resistance Profile
Imatinib	BCR-ABL	Type II (DFG-out)	CHR: 98%, CCyR: 54% in CML (IRIS trial, Phase III) [53]	T315I gatekeeper mutation causes resistance; addressable by ponatinib or asciminib [74].
Osimertinib	EGFR	Covalent (C797)	PFS: 18.9 months (1L NSCLC, FLAURA, Phase III)	C797S tertiary mutation causes resistance; approaches include 4th-gen inhibitors [61].
Asciminib	BCR-ABL	Allosteric (STAMP)	Major molecular response rate 25.5% vs. 13.2% for bosutinib at 96 weeks (ASCEMBL, Phase III) [75]	Resistance via myristoyl pocket mutations; addressable by combination with ATP-competitive agents [75].
Zongertinib	HER2	Covalent (Selective)	ORR: 35% in HER2-mutant NSCLC (Beamion LUNG-1, Phase I/II, 2025 approval) [66]	Spares EGFR, reducing gastrointestinal and dermatological toxicity; IC_{50} selectivity >100-fold HER2 vs. EGFR [66].
Vepdegestrant (ARV-471)	ER	PROTAC degrader	Superior PFS vs. fulvestrant (VERITAC-2, Phase III; ongoing)	Overcomes ligand-binding domain (ESR1) mutations causing endocrine therapy resistance .
Pirtobrutinib	BTK	Non-covalent (reversible)	ORR: 67.3% in heavily pretreated CLL (BRUIN, Phase I/II) [69]	Active against C481S-mutant BTK that abrogates ibrutinib binding [69].

3.6 Comparison With Other Therapeutic Modalities

Kinase inhibitors occupy a distinctive niche within the therapeutic armamentarium [76,77]. Compared to monoclonal antibodies such as trastuzumab–which are highly selective but restricted to extracellular targets, require parenteral administration, and carry high manufacturing costs–small-molecule kinase inhibitors readily penetrate cells, target intracellular domains, and are generally administered orally, enhancing patient convenience and treatment adherence. Advances in allosteric inhibitor design and targeted protein degradation are progressively narrowing the selectivity gap between small molecules and biologics [78,79]. A comparative overview of these modality profiles is illustrated in Figure 2. Compared to conventional cytotoxic chemotherapy, kinase inhibitors provide a mechanistically defined therapeutic approach targeting oncogenic signaling, thereby achieving therapeutic efficacy while substantially sparing normal tissues from the non-selective toxicities–including hematopoietic suppression and alopecia–associated with classical chemotherapy [26]. The emergence of PROTACs introduces a further innovation: catalytic target engagement that enables molecular recycling, potentially reducing required drug concentrations and systemic exposure [28,80].



Figure 2. Comparative radar plot of therapeutic modalities.

4. Discussion

4.1 Scientific Impact: Signal Transduction as a Clinical Tool

The Kinase Chemirevolution has validated a reductionist but powerful hypothesis: that complex disease phenotypes can originate from discrete molecular events and are therefore amenable to targeted molecular intervention. This conceptual shift transformed "signal transduction" from a textbook diagram into a framework for clinical decision-making. The ability to selectively target different kinase conformations (DFG-in versus DFG-out) demonstrated that dynamic, flexible proteins are not intractable drug targets, but rather finely regulated machines with multiple "druggable" intermediate states accessible to rational design.

4.2 Transformation of the Drug Discovery Paradigm

The clinical success of kinase inhibitors catalyzed a fundamental transformation of the oncology drug discovery process—from phenotypic screening toward target-based rational design. It also necessitated the development of companion diagnostics: the prescription of trastuzumab or imatinib is inseparable from the determination of HER2 status or BCR-ABL genotype, respectively. This co-development of therapeutics and diagnostics has become the operational foundation of precision medicine. By 2025, this paradigm has advanced to "liquid biopsy" monitoring, enabling detection of emergent resistance mutations such as EGFR C797S in circulating tumor DNA months before radiographic disease progression—creating an opportunity for preemptive therapeutic switching.

4.3 Industrial and Clinical Implications

Kinase inhibitors remain among the highest-revenue pharmaceutical agents in oncology, yet the market structure is evolving. The blockbuster model—in which a single agent treats a broad, molecularly heterogeneous patient population—is increasingly giving way to precision subgroup targeting based on specific driver mutations (e.g., RET fusions, NTRK fusions). While this fragmentation reduces individual product revenues, it substantially improves the probability of clinical success and the magnitude of patient benefit. From a manufacturing perspective, the complexity of small-molecule synthesis remains substantially lower than that of biological agents, and emerging techniques in mechanochemistry and continuous-flow synthesis are further improving process efficiency and environmental sustainability.

4.4 Challenges: Mechanisms of Resistance

Acquired resistance remains the central clinical challenge limiting the durability of kinase inhibitor therapy. The kinase signaling network is intrinsically adaptive, and pharmacological blockade of a single node reliably exerts selective pressure for the emergence of resistance—a phenomenon metaphorically likened to the Hydra of Greek mythology, where suppressing one pathway frequently reveals or amplifies compensatory routes. A comprehensive understanding of resistance mechanisms is therefore essential for designing effective sequential and combination therapeutic strategies.

4.4.1 On-Target Resistance Mutations

On-target resistance mutations alter the drug-binding interface while preserving catalytic activity. The paradigmatic examples span multiple kinase-inhibitor pairs: T315I in BCR-ABL (imatinib, dasatinib, nilotinib resistance), T790M in EGFR (first- and second-generation inhibitor resistance), C797S in EGFR (osimertinib resistance after T790M), G1202R in ALK (lorlatinib resistance), and C481S in BTK (ibrutinib resistance). Each of these mutations has driven the development of next-generation inhibitors designed to accommodate the altered binding site geometry. For C797S-mediated osimertinib resistance, investigational fourth-generation EGFR inhibitors with modified warhead chemistry or altered binding orientations are currently in early clinical development [61,74].

4.4.2 Off-Target Bypass Pathways

Tumors frequently circumvent kinase inhibition through activation of parallel or downstream signaling nodes that restore proliferative and survival signaling independently of the targeted kinase. Well-characterized examples include MET amplification restoring downstream RAS-ERK and PI3K-AKT signaling in EGFR-inhibitor-treated NSCLC; HER2 amplification bypassing EGFR inhibition; activating PIK3CA mutations enabling continued mTOR pathway signaling despite upstream kinase blockade; and MAPK pathway reactivation through RAS mutations or RAF amplification in RAF/MEK inhibitor-treated melanoma. These off-target mechanisms collectively underscore the need for rational combination strategies that simultaneously suppress multiple pathway nodes [75,76].

4.4.3 Histological Transformation

A clinically recognized and mechanistically distinct form of resistance involves phenotypic conversion of the tumor to a histologically different subtype with altered drug sensitivity. Small cell lung cancer (SCLC) transformation occurs in approximately 3-14% of EGFR-mutant NSCLC patients treated with EGFR inhibitors. This transformation is associated with loss of RB1 and TP53, activation of neuroendocrine transcription programs, and acquisition of a cellular state that

is refractory to EGFR inhibition but sensitive to chemotherapy regimens appropriate for SCLC. Awareness of this resistance mechanism has important implications for rebiopsy strategies in EGFR-inhibitor-treated patients with clinical progression [77].

4.4.4 Polyclonal Resistance and Liquid Biopsy

Advanced next-generation sequencing (NGS) of serial liquid biopsies has revealed that clinical resistance to kinase inhibitors frequently involves multiple distinct clonal subpopulations simultaneously harboring different resistance mechanisms–a phenomenon termed polyclonal resistance. This heterogeneity presents a fundamental challenge for sequential inhibitor strategies, since a subsequent agent effective against one resistance mechanism will exert selective pressure favoring the outgrowth of clones harboring alternative mechanisms. Liquid biopsy platforms enable non-invasive monitoring of clonal evolution over time, potentially allowing earlier identification of emergent resistance and preemptive therapeutic adjustment [78].

4.4.5 Clinical Countermeasures: Combinations and Sequential Strategies

The complexity and heterogeneity of kinase inhibitor resistance has driven the development of rational combination strategies designed to suppress multiple resistance pathways simultaneously. Combinations of ATP-competitive and allosteric inhibitors–exemplified by the "double-clamp" approach combining asciminib with nilotinib or dasatinib in CML–represent one validated paradigm. In solid tumors, vertical pathway blockade (e.g., simultaneous EGFR and MET inhibition) aims to prevent bypass resistance. Increasingly, PROTACs are being evaluated as combination partners with ATP-competitive inhibitors, given their mechanistic complementarity and the expectation that simultaneous target engagement from two distinct binding sites will impose a higher mutational barrier to resistance. Sequential clinical protocols guided by liquid biopsy-detected emergent mutations represent a prospective precision resistance management approach [79].

4.5 Future Directions: The AI and Systems Pharmacology Era

The integration of generative AI into kinase drug discovery is no longer prospective–it is operative. Companies including Insilico Medicine and Exscientia have advanced AI-designed kinase inhibitors into clinical development; rentosertib, a TNIK inhibitor generated by Insilico Medicine's generative chemistry platform, has entered Phase II trials for idiopathic pulmonary fibrosis. AI algorithms are capable of systematically exploring chemical space of a scale that exceeds human intuition, identifying non-obvious allosteric scaffolds and optimizing PROTAC linker geometry for maximal degradation efficiency. Critically, these models are increasingly trained not on individual compound properties but on whole-proteome pharmacological effects, incorporating systems-level network pharmacology principles to predict on- and off-target consequences simultaneously [26].

Autonomous "self-driving laboratories" that integrate robotic synthesis, automated biological screening, and AI-driven experimental design are now operational in several academic and industrial settings, compressing the design-make-test-analyze cycle from months to days. This industrialization of molecular discovery represents the next stage of the Kinase Chemirevolution–one in which the human role shifts from performing experiments to formulating hypotheses and interpreting the outputs of autonomous discovery systems [28].

5. Conclusion

The Kinase Chemirevolution constitutes one of the defining achievements of modern biomedical science. Beginning with the recognition that a phosphoryl group could serve as a binary molecular switch controlling cellular fate, and progressing through successive generations of increasingly sophisticated inhibitors, this field has converted previously fatal malignancies into chronic manageable conditions for millions of patients worldwide. The development of imatinib established the proof-of-concept for targeted therapy; the Lasker Award formally recognized this achievement; and over 70 subsequent FDA approvals have confirmed that the principle scales across diverse oncogene-addicted cancers and immune-inflammatory diseases.

The emerging convergence of covalent and allosteric chemistry, protein degradation technology, structural biology, and AI-driven discovery represents a fourth revolution within the revolution itself. This era promises to address not only the persistent challenge of acquired resistance, but also the exploration of previously undruggable kinase targets and the extension of precision kinase modulation to diseases beyond oncology. The field has moved from attacking cancer to precisely dismantling its molecular machinery–and with generative AI and autonomous laboratories now operational, the pace of progress shows no sign of abating.

Acknowledgements

The authors would like to acknowledge Lovely Professional University, Phagwara for continuous support and encouragement.

Author Contributions

Saminesh Kumar: Writing, Original draft. Stalin Arulsamy: Data Analysis, curation. Rajesh Kumar: Figure Generation. Shivank Sharma: Supervision.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Generative AI Statement

Authors have used the ChatGPT as a helping tool for the improvement of the language and grammatical error detection. Authors take full responsibility for all the statements in this manuscript.

References

[1] Fischer EH, Krebs EG. Conversion of phosphorylase b to phosphorylase a in muscle extracts. Journal of Biological Chemistry. 1955, 216(1), 121-132.
[2] Krebs EG, Fischer EH. The phosphorylase b to a converting enzyme of rabbit skeletal muscle. Biochimica et Biophysica Acta. 1956, 20, 150-157. DOI: 10.1016/0006-3002(56)90273-6
[3] Collins I, Workman P. New approaches to molecular cancer therapeutics. Nature Chemical Biology. 2006, 2(12), 689-700.
[4] Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: An emerging targeting technique for protein degradation in drug discovery. BioEssays. 2018, 40(4), e1700247. DOI: 10.1002/bies.201700247
[5] Lenzen S. A fresh view of glycolysis and glucokinase regulation: History and current status. Journal of Biological Chemistry. 2014, 289(18), 12189-12194. DOI: 10.1074/jbc.R114.557314
[6] Katz A. A century of exercise physiology: Key concepts in regulation of glycogen metabolism in skeletal muscle. European Journal of Applied Physiology. 2022, 122(8), 1751-1772. DOI: 10.1007/s00421-022-04935-1
[7] Liu X. Applications of phosphotyrosine superbinding SH2 domain variants. University of Western Ontario. 2019.
[8] Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Research. 2015, 100, 1-23. DOI: 10.1016/j.phrs.2015.07.010
[9] Candido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, et al. Drugging hijacked kinase pathways in pediatric oncology: Opportunities and current scenario. Pharmaceutics. 2023, 15(2), 664. DOI: 10.3390/pharmaceutics15020664
[10] Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, et al. Target-based small molecule drug discovery for colorectal cancer: A review of molecular pathways and *in silico* studies. Biomolecules. 2022, 12(7), 878. DOI: 10.3390/biom12070878
[11] Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: Oncogenic mechanisms and therapeutic approaches. Oncogene. 2021, 40(24), 4079-4093. DOI: 10.1038/s41388-021-01841-2
[12] Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, Halpin J, et al. Using ancient protein kinases to unravel a modern cancer drug's mechanism. Science. 2015, 347(6224), 882-886. DOI: 10.1126/science.aaa1823
[13] Kurillová A, Kvítek L, Panáček A. Innovative approaches in cancer treatment: emphasizing the role of nanomaterials in tyrosine kinase inhibition. Pharmaceutics. 2025, 17(6), 783. DOI: 10.3390/pharmaceutics17060783
[14] Miao YR, Rankin EB, Giaccia AJ. Therapeutic targeting of the functionally elusive TAM receptor family. Nature Reviews Drug Discovery. 2024, 23(3), 201-217. DOI: 10.1038/s41573-023-00846-8
[15] Nussinov R, Jang H, Tsai CJ, Cheng F. Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. PLOS Computational Biology. 2019, 15(3), e1006658. DOI: 10.1371/journal.pcbi.1006658
[16] Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Using genome sequence to enable the design of medicines and chemical probes. Chemical Reviews. 2018, 118(4), 1599-1663. DOI: 10.1021/acs.chemrev.7b00504
[17] Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nature Reviews Drug Discovery. 2018, 17(3), 183-196. DOI: 10.1038/nrd.2017.226
[18] Kattner P, Zeiler K, Herbener VJ, Ferla-Brühl K, Kassubek R, Grunert M, et al. What animal cancers teach us about human biology. Theranostics. 2021, 11(14), 6682-6702. DOI: 10.7150/thno.56623
[19] Sheetz JB. The dead receptor paradox: Insights into receptor tyrosine kinases with intracellular pseudokinase domains. Yale University. 2022.
[20] Cutolo EA, Campitiello R, Caferri R, Pagliuca VF, Li J, Agathos SN, et al. Immunomodulatory compounds from the sea: From the origins to a modern marine pharmacopoeia. Marine Drugs. 2024, 22(7), 304. DOI: 10.3390/md22070304
[21] Zhang L, Song J, Kong L, Yuan T, Li W, Zhang W, et al. The strategies and techniques of drug discovery from natural products. Pharmacology & Therapeutics. 2020, 216, 107686. DOI: 10.1016/j.pharmthera.2020.107686
[22] Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery. 2018, 17(1), 19-33. DOI: 10.1038/nrd.2017.194

[23] Gehringer M. Covalent kinase inhibitors: An overview. Protein Kinase Inhibitors. Springer, Cham. 2020, 43-94. DOI: 10.1007/7355_2020_103
[24] Hillebrand L, Liang XJ, Serafim RAM, Gehringer M. Emerging and re-emerging warheads for targeted covalent inhibitors: An update. Journal of Medicinal Chemistry. 2024, 67(10), 7668-7758. DOI: 10.1021/acs.jmedchem.3c01825
[25] Collins I, Wang H, Caldwell JJ, Chopra R. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. Biochemical Journal. 2017, 474(7), 1127-1147. DOI: 10.1042/BCJ20160762
[26] Hartung T. AI, agentic models and lab automation for scientific discovery–the beginning of scAInce. Frontiers in Artificial Intelligence. 2025, 8, 1649155. DOI: 10.3389/frai.2025.1649155
[27] Martinengo B, Diamanti E, Uliassi E, Bolognesi ML. Medicinal chemistry: A key driver in achieving the global sustainable development goals. Journal of Medicinal Chemistry. 2025, 68(7), 6916-6931. DOI: 10.1021/acs.jmedchem.4c03016
[28] Brvar M, O'Neill TJ, Plettenburg O, Krappmann D. An updated patent review of MALT1 inhibitors (2021-present). Expert Opinion on Therapeutic Patents. 2025, 35(6), 639-656. DOI: 10.1080/13543776.2025.2484371
[29] Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, et al. Advancements in protein kinase inhibitors: From discovery to clinical applications. Research. 2025, 8, 0747. DOI: 10.34133/research.0747
[30] Gresham G, Meinert JL, Gresham AG, Piantadosi S, Meinert CL. Update on the clinical trial landscape: Analysis of ClinicalTrials.gov registration data, 2000-2020. Trials. 2022, 23(1), 858. DOI: 10.1186/s13063-022-06569-2
[31] Miao Q, Wang FY. Artificial intelligence for science (AI4S): Frontiers and perspectives based on parallel intelligence. Cham: Springer. 2024. DOI:10.1007/978-3-031-67419-8
[32] Paul A, Srinivasan N. Genome-wide and structural analyses of pseudokinases encoded in the genome of Arabidopsis thaliana provide functional insights. Proteins. 2020, 88(12), 1620-1638. DOI: 10.1002/prot.25981
[33] Wiewiora RP. Rigorous construction of markov state models for conformationally selective drug design. Weill Medical College of Cornell University. 2020.
[34] Sisó S, Kavirayani AM, Couto S, Stierstorfer B, Mohanan S, Morel C, et al. Trends and challenges of the modern pathology laboratory for biopharmaceutical research excellence. Toxicologic Pathology. 2025, 53(1), 5-20. DOI: 10.1177/01926233241303898
[35] Kodumuru R, Sarkar S, Parepally V, Chandarana J. Artificial intelligence and internet of things integration in pharmaceutical manufacturing: A smart synergy. Pharmaceutics. 2025, 17(3), 290. DOI: 10.3390/pharmaceutics17030290
[36] Mukohara T. Vepdegestrant for the treatment of HR+/HER2− breast cancer. Expert Opinion on Pharmacotherapy. 2025, 26(7), 791-799. DOI: 10.1080/14656566.2025.2488456
[37] Dedigama Arachchige PM. Development of tools for phosphosite-specific kinase identification and discovery of phosphatase substrates. Wayne State University. 2017.
[38] da Silva SR. Investigating the inhibition of ubiquitin-like activating enzymes. University of Toronto. 2016.
[39] Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, et al. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. Journal of Medicinal Chemistry. 2015, 58(1), 466-479. DOI: 10.1021/jm501603h
[40] Yadav S, Mathur P. Orthosteric and allosteric modulation of human kinases: A mechanistic view. Frontiers in Bioscience-Landmark. 2020, 25(8), 1462-1487. DOI: 10.2741/4864
[41] Yurtsever Z, Patel DA, Kober DL, Su A, Miller CA, Romero AG, et al. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochimica et Biophysica Acta. 2016, 1860(11), 2335-2344. DOI: 10.1016/j.bbagen.2016.06.023
[42] Angiolini M. The role of structural biology in kinase inhibitor drug discovery success. Structural Biology in Drug Discovery: Methods, Techniques, and Practices. 2020, 363-393. DOI: 10.1002/9781118681121.ch16
[43] Fischer PM. Approved and experimental small-molecule oncology kinase inhibitor drugs: A mid-2016 overview. Medicinal Research Reviews. 2017, 37(2), 314-367. DOI: 10.1002/med.21409
[44] Meng F, Liang Z, Zhao K, Luo C. Drug design targeting active posttranslational modification protein isoforms. Medicinal Research Reviews. 2021, 41(3), 1701-1750. DOI: 10.1002/med.21774
[45] Voice A. Modelling the Reactivity of Cysteine Targeting Covalent Inhibitors. University of Bristol. 2021.
[46] Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R. Advances in covalent kinase inhibitors. Chemical Society Reviews, 2020, 49(9), 2617-2687. DOI: 10.1039/C9CS00720B
[47] Castelli S. Quantitative proteomic approaches to study drug mechanism of action. Università degli Studi di Milano. 2023.
[48] Sampaio MM, Santos MLC, Marques HS, Gonçalves VLS, Araújo GRL, Lopes LW, et al. Chronic myeloid leukemia–from the Philadelphia chromosome to specific target drugs: A literature review. World Journal of Clinical Oncology. 2021, 12(2), 69. DOI: 10.5306/wjco.v12.i2.69
[49] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. 2004, 350(21), 2129-2139. DOI: 10.1056/NEJMoa040938
[50] Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004, 304(5676), 1497-1500. DOI: 10.1126/science.1099314
[51] Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine. 2001, 344(14), 1031-1037. DOI: 10.1056/NEJM200104053441401
[52] Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 2000, 289(5486), 1938-1942. DOI: 10.1126/science.289.5486.1938
[53] Link W. Principles of cancer treatment and anticancer drug development. Springer. 2019.
[54] Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: Kinase inhibitors and beyond. Endocrine Reviews. 2019, 40(6), 1573-1604. DOI: 10.1210/er.2019-00007
[55] Behranvand N, Nasri F, Zolfaghari Emameh R, Khani P, Hosseini A, Garssen J, et al. Chemotherapy: A double-edged sword in cancer treatment. Cancer Immunology, Immunotherapy. 2022, 71(3), 507-526. DOI: 10.1007/s00262-021-03013-3

[56] Mustapha A, Ismail A, Abdullahi SU, Hassan ON, Ugwunnaji PI, Balogun SM, et al. Cancer chemotherapy: A review update of the mechanisms of actions, prospects and associated problems. BIOMED Natural and Applied Science. 2021, 1(1), 1-19. DOI: 10.53858/bnas01010119
[57] Agarwal SM, Pal D, Gupta M, Saini R. Insight into discovery of next generation reversible TMLR inhibitors targeting EGFR activating and drug resistant T790M mutants. Current Cancer Drug Targets. 2017, 17(7), 617-636. DOI: 10.2174/1568009617666170330112842
[58] Toenjes S. Conformational control: A strategy to increase kinase inhibitor selectivity. San Diego State University. 2020.
[59] Warnecke B, Nagasaka M. Beyond first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI): approach to resistance. Advances in Oncology. 2024, 4(1), 63-72. DOI: 10.1016/j.yao.2024.01.008
[60] Qureshi R, Zou B, Alam T, Wu J, Lee VHF Yan H. Computational methods for the analysis and prediction of EGFR-mutated lung cancer drug resistance: Recent advances in drug design, challenges and future prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics. 2022, 20(1), 238-255. DOI: 10.1109/TCBB.2022.3141697
[61] Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences. 2001, 98(15), 8554-8559. DOI: 10.1073/pnas.141230798
[62] Suessmuth RD, Kulike-Koczula M, Gao P, Kosol S. Fighting antimicrobial resistance: Innovative drugs in antibacterial research. Angewandte Chemie International Edition. 2025, 64(10), e202414325. DOI: 10.1002/anie.202414325
[63] Kharkar PS. Computational approaches for the design of (mutant-)selective tyrosine kinase inhibitors: State-of-the-art and future prospects. Current Topics in Medicinal Chemistry. 2020, 20(17), 1564-1575. DOI:10.2174/1568026620666200502005853
[64] Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Molecular Cancer. 2022, 21(1), 99. DOI: 10.1186/s12943-021-01434-3
[65] Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q. Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation. Chemical Society Reviews. 2022, 51(13), 5330-5350. DOI: 10.1039/d1cs00762a
[66] Cusack KP, Wang Y, Hoemann MZ, Marjanovic J, Heym RG, Vasudevan A. Design strategies to address kinetics of drug binding and residence time. Bioorganic and Medicinal Chemistry Letters. 2015, 25(10), 2019-2027. DOI: 10.1016/j.bmcl.2015.02.027
[67] Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: A next-generation strategy. Expert Opinion on Drug Discovery. 2019, 14(12), 1237-1253. DOI: 10.1080/17460441.2019.1660641
[68] Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: Progress, challenges and future directions. Molecular Cancer. 2018, 17(1), 48. DOI: 10.1186/s12943-018-0804-2
[69] Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase inhibitors and kinase-targeted cancer therapies: Recent advances and future perspectives. International Journal of Molecular Sciences. 2024, 25(10), 5489. DOI: 10.3390/ijms25105489
[70] Tassinari E, Milelli A. Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease. RSC Medicinal Chemistry. 2025, 16(12), 5862-5872. DOI: 10.1039/d5md00681c
[71] Scalzulli E, Carmosino I, Bisegna ML, Martelli M, Breccia M. CML resistant to 2nd-generation TKIs: Mechanisms, next steps, and new directions. Current Hematologic Malignancy Reports. 2022, 17(6), 198-205. DOI: 10.1007/s11899-022-00683-3
[72] De SK. Asciminib: First FDA-approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia. Medicinal Chemistry Research. 2023, 32(3), 424-433. DOI: 10.1007/s00044-022-03011-9
[73] Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023, 142(1), 62-72. DOI: 10.1182/blood.2022018674
[74] Ferguson FM, Gray NS. Kinase inhibitors: The road ahead. Nature Reviews Drug Discovery. 2018, 17(5), 353-377. DOI: 10.1038/nrd.2018.21
[75] Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nature Reviews Drug Discovery. 2021, 20(7), 551-569. DOI: 10.1038/s41573-021-00195-4
[76] Duran-Frigola M, Cigler M, Winter GE. Advancing targeted protein degradation via multiomics profiling and artificial intelligence. Journal of the American Chemical Society. 2023, 145(5), 2711-2732. DOI: 10.1021/jacs.2c11098
[77] Willis RE. Targeted cancer therapy: Vital oncogenes and a new molecular genetic paradigm for cancer initiation progression and treatment. International Journal of Molecular Sciences. 2016, 17(9), 1552. DOI: 10.3390/ijms17091552
[78] Niazi SK, Mariam Z. Artificial intelligence in drug development: Reshaping the therapeutic landscape. Therapeutic Advances in Drug Safety. 2025, 16, 20420986251321704. DOI: 10.1177/20420986251321704
[79] Gangwal A, Lavecchia A. Artificial intelligence in natural product drug discovery: current applications and future perspectives. Journal of Medicinal Chemistry. 2025, 68(4), 3948-3969. DOI: 10.1021/acs.jmedchem.4c01257
[80] Verma R, Mohl D, Deshaies RJ. Harnessing the power of proteolysis for targeted protein inactivation. Molecular Cell. 2020, 77(3), 446-460. DOI: 10.1016/j.molcel.2020.01.010



Supplementary Figure 1. PRISMA flow diagram–literature search and study selection.
PRISMA flow diagram documenting the systematic literature search strategy, screening, eligibility assessment, and final inclusion. Records were sourced from PubMed, Web of Science,Scopus, PDB, and ClinicalTrials.gov, supplemented by patent filings, FDA databases, and industry press releases. Studies were excluded if purely computational without experimental validation, if they involved clinically non-translatable non-selective inhibitors (retained for historical context only), or if they failed pre-specified quality thresholds (crystallographic resolution ≤2.5 Å; R^2 ≥0.6; Q^2≥0.5).